Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

MaPLe

Title

Molecular Profiling for Lymphoma

Description

This study concentrates on patients having a suspected or confirmed diagnosis of diffuse large B-cell lymphoma or follicular lymphoma grade 3b who may be suitable for targeted therapy either immediately or subsequently in the course of their illness. Lymphoma samples will be taken from the lymph node or extra nodal sites at either the time of first presentation or time of recurrence. 

Objectives

The objectives of this study are:

  • To aid the identification of patients with lymphoma that may be suitable for specific targeted therapies.
  • To test whether molecular characterisation of lymphoma can be carried out as a standardised, routine practice during the treatment of patients in the NHS.
  • To capture routine clinical data to form a cohort dataset of gene changes, treatments and outcomes.
  • To relate the changes found in lymphoma biopsy samples to those seen in cfDNA in the blood.

Study Design

This is a multicentre prospective observational cohort study for the collection of tumour samples and matched blood samples from patients with suspected or confirmed diffuse large B-cell lymphoma or grade 3b follicular lymphoma.  

Study Status

Closed to recruitment 31.08.21 - currently in follow-up.

Population

3000 patients with DLBCL or grade 3b follicular lymphoma. Patients can be recruited at initial diagnosis or at the time of relapse or disease progression. 

 

Blood Cancer UK logo

This trial is funded by Blood Cancer UK (formerly Bloodwise) - award reference no. 19011

Study Team:

Senior Trial Manager:

Josh Caddy

Trial Coordinator:

Ben Lindfield

Clinical Data Coordinator:

Peter Navin

 

Contact information:

Email: maple@soton.ac.uk

SAE reporting:

Email: ctu@soton.ac.uk

 

Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R, et al. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia. 2020;34(5):1329-41. https://doi.org/10.1038/s41375-019-0691-6

Privacy Settings